For research use only. Not for therapeutic Use.
Samuraciclib hydrochloride（Cat No.:I020270）is a selective cyclin-dependent kinase 7 (CDK7) inhibitor under investigation for its anticancer potential. By inhibiting CDK7, a key regulator of transcription and the cell cycle, Samuraciclib disrupts the transcription of genes crucial for cancer cell proliferation and survival. This leads to cell cycle arrest, reduced tumor growth, and induction of apoptosis, particularly in cancers with high transcriptional dependency. It is being explored as a treatment for various solid tumors, including breast cancer, and is often studied in combination with other therapies to enhance its therapeutic efficacy.
| Catalog Number | I020270 |
| CAS Number | 1805789-54-1 |
| Molecular Formula | C₂₂H₃₁ClN₆O |
| Purity | ≥95% |
| IUPAC Name | (3R,4R)-4-[[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]piperidin-3-ol;hydrochloride |
| InChI | InChI=1S/C22H30N6O.ClH/c1-15(2)18-13-26-28-21(25-11-16-6-4-3-5-7-16)10-20(27-22(18)28)24-12-17-8-9-23-14-19(17)29;/h3-7,10,13,15,17,19,23,25,29H,8-9,11-12,14H2,1-2H3,(H,24,27);1H/t17-,19+;/m1./s1 |
| InChIKey | YMNPLAHCOLEZJE-ZFNKBKEPSA-N |
| SMILES | CC(C)C1=C2N=C(C=C(N2N=C1)NCC3=CC=CC=C3)NC[C@H]4CCNC[C@@H]4O.Cl |
| Reference | [1]. Patel H, et al. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Mol Cancer Ther. 2018 Jun;17(6):1156-1166.<br>[2]. Hazel P, et al. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study. ChemMedChem. 2017 Mar 7;12(5):372-380. |
